Top Story

Cosentyx bested Stelara in patient-reported plaque psoriasis outcomes

November 9, 2017

Many patient-reported outcomes for moderate-to-severe plaque psoriasis were better in individuals treated with Cosentyx than in those treated with Stelara, recent data suggest.

Investigators assessed 16- and 52-week pain, itching, scaling, and Dermatology Life Quality Index (DLQI) response in 336 patients treated with Cosentyx (secukinumab, Novartis) and 339 patients treated with Stelara (ustekinumab, Janssen).

In the Journals

Psoriasis, inflammatory diseases increase risk for cirrhosis, fatty liver

November 2, 2017
Patients with inflammatory disorders, especially psoriasis and psoriatic arthritis, had an elevated risk for severe liver disease such as nonalcoholic fatty liver…
In the Journals

Adalimumab associated with improvements in nail psoriasis

October 31, 2017
Twenty-six weeks of treatment with adalimumab was associated with improvements in a number of fingernail psoriasis outcomes compared with placebo, according to recent…

Risankizumab superior to other biologics for psoriasis in three trials

October 27, 2017
Results of three phase 3 studies involving the IL-23 inhibitor risankizumab showed that the drug met Psoriasis Area and Severity Index endpoints and was superior to…
More Headlines »